Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. - Blauvelt, Andrew; Lomaga, Mark; Burge, Russel; Zhu, Baojin; Shen, Wei; Shrom, David; Dossenbach, Martin; Pinter, Andreas (Journal of Dermatological Treatment, 2020)